secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phio Pharmaceuticals Corp. (PHIO)
CIK:        0001533040
Form:       8-K
Filed at:   2024-07-02T23:59:59+00:00
Accession:  0001683168-24-004619
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 3.03, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phio Pharmaceuticals implements 1-for-9 reverse stock split effective July 5, 2024
--------------------------------------------------------------------------------

- Reverse split ratio set at 1-for-9; reduces outstanding shares from ~4.6M to ~0.5M.
- Split effective 12:01 a.m. ET on July 5, 2024; trading symbol remains PHIO.
- Adopted to meet Nasdaq minimum $1.00 bid price requirement for continued listing.
- No fractional shares issued; cash payment in lieu for fractional holdings.
- CUSIP changed to 71880W501; transfer agent Computershare managing exchange.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533040/000168316824004619/0001683168-24-004619-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533040/000168316824004619/phio_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-004619

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer